Tempest Therapeutics Inc
TPST
Get informed when a big investor buys or sells
+ FollowMarket Cap$15.47M
Close$
$-0.10
112.3% downside
Current Fair Value
112.3% downsideOvervalued by 112.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.47 Million |
|---|---|
| Enterprise Value | $22.25 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.33 |
| Beta | -1.66 |
| Outstanding Shares | 15,223,972 |
Return
| Return on Equity | 3713.03% |
|---|---|
| Return on Assets | -420.14% |
| Return on Invested Capital | -783.08% |
Valuation & Multiples
| P/E Ratio | -0.22 |
|---|---|
| PEG | 0.65 |
| Price to Sales | - |
| Price to Book Ratio | -0.85 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.55 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.34 |
| Debt to Equity | -6.94 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.73%▲ 2.00% |
|---|---|
| Total Invested | $1.14M▲ 34.09% |
| Investors Holding | 19▼ 1.00% |
ESG Score
No data
About Tempest Therapeutics Inc
13 employees
CEO: Julia Owens Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct and t...